The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials
Angela Genge,Jesse M Cedarbaum,Jeremy Shefner,Adriano Chio,Ammar Al-Chalabi,Philip Van Damme,Chris McDermott,Jonathan Glass,James Berry,Ruben P A van Eijk,Christina Fournier,Julian Grosskreutz,Jinsy Andrews,Vanessa Bertone,Tommy M Bunte,Mathias Couillard,Cathy Cummings,Gale Kittle,John Polzer,Kristiana Salmon,Corey Straub,Leonard H van den Berg,Angela GengeJesse M. CedarbaumJeremy ShefnerAdriano ChioAmmar Al-ChalabiPhilip Van DammeChris McDermottJonathan GlassJames BerryRuben P.A. van EijkChristina FournierJulian GrosskreutzJinsy AndrewsVanessa BertoneTommy M BunteMathias CouillardCathy CummingsGale KittleJohn PolzerKristiana SalmonCorey StraubLeonard H. van den Berg1 Montreal Neurological Institute-Hospital,ALS Center of Excellence,Montreal,Quebec,Canada2 Yale School of Medicine,Section of Movement Disorders,Coeruleus Clinical Sciences LLC,Woodbridge,CT,USA3 Barrow Neurological Institute,Phoenix,AZ,USA4 Department of Neuroscience,University of Turin,Torino,Italy5 Department of Basic and Clinical Neuroscience,King's College London,Institute of Psychiatry Psychology and Neuroscience,Maurice Wohl Clinical Neuroscience Institute,London,UK6 Department of Neurology,KU Leuven,Leuven,Belgium7 Department of Neurology,The University of Sheffield,Sheffield,UK8 Department of Neurology,Emory University,Atlanta,GA,USA9 Massachusetts General Hospital,Neurology,Boston,MA,USA10 Department of Neurology and Biostatistics,UMC Utrecht Hersencentrum Rudolf Magnus,Utrecht,Netherlands11 Precision Neurology of Neuromuscular and Motoneuron Diseases,University of Lübeck,Lübeck,Germany12 Columbia Presbyterian Medical Center,Neurology,New York,NY,USA13 Montreal Neurological Institute and Hospital,McGill University,Montreal,QC,Canada14 Department of Neurology,UMC Utrecht Hersencentrum Rudolf Magnus,Utrecht,Netherlands15 International Alliance of ALS/MND Associations,Northampton,Northamptonshire,UK,and16 QurAlis,Cambridge,MA,USA
DOI: https://doi.org/10.1080/21678421.2024.2320880
2024-02-24
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Abstract:The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) was developed more than 25 years ago as an instrument to monitor functional change over time in patients with ALS. It has since been revised and extended to meet the needs of high data quality in ALS trials (ALSFRS-R), however a full re-validation of the scale was not completed. Despite this, the scale has remained a primary outcome measure in clinical trials. We convened a group of clinical trialists to discuss and explore opportunities to improve the scale and propose alternative measures. In this meeting report, we present a call to action on the use of the ALSFRS-Revised scale in clinical trials, focusing on the need for (1) harmonization of the ALSFRS-R administration globally, (2) alignment on a set of recommendations for clinical trial design and statistical analysis plans (SAPs), and (3) use of additional outcome measures.
clinical neurology